dpp-4-piol

DPP-4-PIOL is an antagonist of GABAA. In dentate gyrus granule cells, it acts by selectively antagonizing tonic over phasic GABAergic currents.

DPP-4/GPR119 modulator 2 is an inhibitor of dipeptidyl peptidase IV (DPP-IV) (IC50: 0.22 μM) and an agonist of GPR119 (EC50: 0.95 μM).

Compound 5a, also known as DPP-4 inhibitor 3, is a powerful dipeptidyl peptidase IV (DPP-IV) inhibitor, demonstrating an IC50 value of 0.75 nM. It exhibits outstanding antioxidant and insulinotropic activity [1].

DPP-4-IN-1 (compound d1) is a highly potent inhibitor of DPP-4 (dipeptidyl peptidase 4) with an IC 50 of 49 nM, making it suitable for diabetes research [1]. It shares structural similarities to Alogliptin and can be effectively utilized for studying diabetes-related mechanisms.

DPP-4-IN-8 (compound 27) is a potent and selective inhibitor of dipeptidyl peptidase 4 (DPP4), with an inhibition constant (Ki) of 0.96 μM. It inhibits the dipeptidase activity of DPP4 in both Caco-2 and HepG-2 cells and dose-dependently reduces the expression of chemokines such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) [1].

DPP-4-IN-2 (compound b2) is a structural analog of Alogliptin that can be used for the research of diabetes. DPP-4-IN-2 is a potent dipeptidyl peptidase 4 (DPP-4) inhibitor with an IC50 value of 79 nM [1].

DPP-4/GPR119 modulator 1 (Compound 22) is an orally active compound that functions as both a dipeptidyl peptidase IV (DPP-IV) inhibitor and GPR119 agonist. It demonstrates a glucose-lowering effect in blood and exhibits moderate inhibition of the hERG channel, with an IC50 value of 4.9 µM. This compound is applicable in diabetes research [1].